The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA 2018 | Interim phase II results of azacitidine for acute GvHD prophylaxis

Jun 25, 2018

On Saturday 16 thJune, during the 23 rd Congress of EHA (European Hematology Association), Stockholm, Sweden, a poster ( PS1471) by Mark Schroederfrom Washington University School of Medicine, St. Louis, USA,   et al. titled “A phase I/II trial of intravenous azacitidine for acute GvHD prophylaxis in patients undergoing matched unrelated stem cell transplantation: interim phase II results” was presented.

Based on previous studies assessing azacitidine in pre-clinical models, Schroeder and colleagues conducted a phase I/II study to evaluate the safety and efficacy of azacitidine after transplantation for the prevention of acute graft-versus-host disease (aGvHD) and relapse in patients undergoing matched unrelated stem cell transplantation.

Patients and methods:

  • Median age = 59 years (range, 24–70)
  • N = 35 of 46 patients received transplantation and study drug to date
  • Patients received either myeloablative or reduced intensity conditioning without antithymocyte globulin
  • Azacitidine was administered IV on Day +7 for five consecutive days and repeated every 28 days for a total of four cycles after allogeneic transplant
  • GvHD prophylaxis: mini-methotrexate and tacrolimus
  • The recommended phase II dose from phase I: 45 mg/m 2

Key findings:

  • Median follow up: 248 days (range, 27–891)
  • Primary graft failure: one subject related to HHV6 infection
  • Median ANC engraftment: 14 days
  • Median platelet engraftment: 19 days (range, 10–NR)
  • Acute GvHD incidence grade II – IV: 15 patients (43%)
  • Acute GvHD incidence grade III/IV: 7 patients (20%)
  • Incidence of steroid refractory GvHD: 7 patients
  • Four patients have relapsed
  • Most common non-hematologic grade 3 or 4 AEs: gastrointestinal toxicity, electrolyte abnormalities, and infections

In summary, azacitidine can be used safely as GvHD prophylaxis starting at day +7 after matched unrelated donor transplantation up to a dose of 45mg/m 2. Phase II enrolment and follow up is ongoing.

  1. Schroeder M . et al.A phase I/II trial of intravenous azacitidine for acute GvHD prophylaxis in patients undergoing matched unrelated stem cell transplantation: interim phase II results. Abstract PS1471. 23 rdCongress of the European Hematology Association  (EHA).